An analysis of rate filings from small group insurers indicates that small businesses may face a median premium increase of 14% in 2027. The filings identify rising healthcare costs and increased utilization as primary factors, specifically highlighting the financial impact of specialty drugs. Insurers explicitly cite GLP-1 medications as a significant driver behind these escalating costs and subsequent premium hikes.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.